echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > A new drug candidate for the treatment of type 2 diabetes

    A new drug candidate for the treatment of type 2 diabetes

    • Last Update: 2022-09-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Figure: The new drug candidate (GLP-1/tesaglitazar) improves weight, feed intake, and glucose metabolism


    Credits: Helmholtz Munich

    The research team from Helmholtz Munich, the German Diabetes Research Center (DZD) and Novo Nordisk has developed a new combination of hormones for the future treatment of type 2 diabetes


    The drug tesaglitazar improves glucose and fat metabolism


    This new drug improves glucose tolerance and glucose metabolism

    The new drug has been successfully tested in animal studies: "Obese and diabetic male mice had much greater improvements in glucose metabolism compared to treatment with the GLP-1 hormone or Tesaglitazar alone, and there were no damaging adverse effects on the liver or kidneys," said


    The researchers now want to investigate whether the drug also has the potential to treat type 2 diabetes in humans, and whether the efficacy of this new combination therapy can be further optimized


    GLP-1-mediated delivery of Tesaglitazar improves obesity and glucose metabolism in male mice

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.